A novel rapamycin derivative, designated RTB-101, has demonstrated significant geroprotective effects in the first randomized, placebo-controlled human longevity trial, according to results presented at the International Conference on Aging Research.
The Phase 2 trial enrolled 450 healthy adults aged 65 to 80 and found that participants receiving low-dose RTB-101 for 12 months showed improved immune function, enhanced metabolic health, and a 30% reduction in respiratory infections compared to the placebo group.
RTB-101 works by partially inhibiting the mTOR pathway, a cellular signaling network that regulates growth and metabolism. While the parent compound rapamycin has long been known to extend lifespan in laboratory animals, its immunosuppressive side effects have limited its use in healthy humans. The new derivative appears to selectively modulate mTOR signaling without compromising immune defense.
"These results represent a genuine milestone in translational geroscience," said Dr. Joan Mannick, who led the trial. "We are seeing measurable rejuvenation of the immune system in elderly individuals, with a favorable safety profile."
A larger Phase 3 trial is now being planned, and researchers hope to gain regulatory approval for RTB-101 as the first FDA-approved geroprotective medication within the next five years.